Clinical trial
A Phase II, Randomized Study of the Safety and Efficacy of Hydroxyurea in Subjects on Potent Antiretroviral Therapy With Less Than 200 Copies/ml of HIV RNA in the Plasma
NCT00000916 is registered in ClinicalTrials.gov with National Institute of Allergy and Infectious Diseases (NIAID) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II, Randomized Study of the Safety and Efficacy of Hydroxyurea in Subjects on Potent Antiretroviral Therapy With Less Than 200 Copies/ml of HIV RNA in the Plasma
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- Not reported
- Completion date
- August 31, 2004
- Enrollment
- 399
- Sites
- 34
Conditions
As the registry lists them; a condition with its own page is linked.